Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination
New COVID-19 vaccines should target both systemic and mucosal immunity, to establish a first line of immune defence at the mucosal barrier. This would benefit vulnerable patient populations and may help to eradicate SARS-CoV-2 circulation.
Authors
- Rachel Wake (ORCID: https://orcid.org/0000-0003-3193-4888)
- Matthew J. Paul (ORCID: https://orcid.org/0000-0002-0852-8788)
- Nicole Falci Finardi (ORCID: https://orcid.org/0000-0003-2204-7582)
- Richard J. Cook (ORCID: https://orcid.org/0000-0002-1414-4908)
- Nidhi Sofat (ORCID: https://orcid.org/0000-0002-6963-6475)
- Elisabetta Groppelli (ORCID: https://orcid.org/0000-0003-4241-2858)
- Julian K‐C. (ORCID: https://orcid.org/0000-0003-0767-0042)
- Mohammed T Hudda (ORCID: https://orcid.org/0000-0001-7894-1159)
- Scott J C Pallett (ORCID: https://orcid.org/0000-0002-9465-5299)
- Kathryn Biddle (ORCID: https://orcid.org/0000-0001-5267-200X)
- Soraya Koushesh
- Eugenia Boariu
- Louis Dwyer-Hemmings
Institutions
- Guy's Hospital (GB)
- St George's, University of London (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
- Dasman Diabetes Institute (KW)
Publication Details
- Journal
- Vaccine
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127175
- Citations
- 10
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 13.96
Funders
- European Commission
- Austrian Science Fund
- Universität für Bodenkultur Wien
- EQUIPMENT BOKU VIENNA INSTITUTE OF BIOTECHNOLOGY
- Merck Sharp and Dohme
- Biotechnology and Biological Sciences Research Council
- St. George's, University of London